454 related articles for article (PubMed ID: 33887983)
1. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
Qiu M; Ding LL; Zhang M; Zhou HR
Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials.
Kani R; Watanabe A; Miyamoto Y; Ejiri K; Iwagami M; Takagi H; Slipczuk L; Tsugawa Y; Aikawa T; Kuno T
J Am Heart Assoc; 2024 Feb; 13(3):e031805. PubMed ID: 38293914
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Donnan JR; Grandy CA; Chibrikov E; Marra CA; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM
BMJ Open; 2019 Feb; 9(1):e022577. PubMed ID: 30813108
[TBL] [Abstract][Full Text] [Related]
4. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
Lin DS; Lee JK; Chen WJ
J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
[TBL] [Abstract][Full Text] [Related]
5. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
McGill JB; Subramanian S
Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
7. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
8. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Rigato M; Fadini GP; Avogaro A
Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697
[TBL] [Abstract][Full Text] [Related]
9. Safety of SGLT2 Inhibitors in Three Chronic Diseases.
Ge S; Liu R; Mao Y; Geng C; Wang H; Song K; Tian QB
Int Heart J; 2023; 64(2):246-251. PubMed ID: 37005318
[TBL] [Abstract][Full Text] [Related]
10. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.
Milder TY; Stocker SL; Day RO; Greenfield JR
Drug Saf; 2020 Dec; 43(12):1211-1221. PubMed ID: 33095409
[TBL] [Abstract][Full Text] [Related]
11. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
[TBL] [Abstract][Full Text] [Related]
15. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
17. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
Bai Y; Jin J; Zhou W; Zhang S; Xu J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1365-1374. PubMed ID: 33812735
[TBL] [Abstract][Full Text] [Related]
18. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cao H; Rao X; Jia J; Yan T; Li D
Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
